ASTEC: Automatic selection of clinical trials based on eligibility criteria

被引:1
|
作者
Cuggia, M. [1 ]
Dufour, J. -C. [2 ]
Zekri, O. [3 ]
Gibaud, I. [4 ]
Garde, C. [5 ]
Bohec, C. [6 ]
Duvauferrier, R. [1 ]
Fieschi, D. [2 ]
Besana, P. [1 ]
Charlois, L. [2 ]
Bourde, A. [1 ]
Garcelon, N. [1 ]
Laurent, J. [3 ]
Fieschi, M. [2 ]
Dameron, O. [1 ]
机构
[1] Univ Rennes 1, INSERM, UMR 936, F-35043 Rennes, France
[2] Univ Aix Marseille, LERTIM, F-13005 Aix Marseille, France
[3] CRLCC Ctr Eugene Marquis, Rennes, France
[4] SIB, Rennes, France
[5] ENOVACOM, Marseille, France
[6] Reseau Onco, F-35042 Bretagne, France
关键词
D O I
10.1016/j.irbm.2012.02.001
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Automatic Selection of clinical Trial based on Eligibility Criteria (ASTEC) project is to automate, so as to make it systematic, the search of cancer clinical trials, by reusing the patient data contained into an oncologic electronic health record. ASTEC project tackles two major scientific challenges for medical informatics: 1) the syntactic and semantic interoperability between information systems. The oncologic electronic medical records and the recruitment decision system must be interoperable. The ASTEC project proposes a framework of syntactico-semantic interoperability based on international standards. Generic methods of mediation and reasoning based on ontologies are developed to match data from the electronic medical records to the inclusion/exclusion criteria of clinical trials; 2) a decision support system for recruitment. We have developed inference methods on the electronic medical records adapted to the data structure as well as the eligibility criteria, this paper, we present and justify our choices, concerning the medical process in oncology and the scientific and technical aspects. Furthermore the system will be evaluated in real time. The aim is to demonstrate a significative improvement of the prescreening rate of patient. (C) 2012 Published by Elsevier Masson SAS.
引用
收藏
页码:150 / 164
页数:15
相关论文
共 50 条
  • [31] Eligibility criteria for phase I clinical trials: tight vs loose?
    Malik, Laeeq
    Lu, David
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 999 - 1002
  • [32] Use of modernized eligibility criteria in pancreatic cancer clinical trials.
    Riner, Andrea N.
    Freudenberger, Devon Clemons
    Herremans, Kelly M.
    Neal, Daniel W.
    Vudatha, Vignesh
    George, Thomas J.
    Trevino, Jose G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Classifying Eligibility Criteria in Clinical Trials Using Active Deep Learning
    Chuan, Ching-Hua
    2018 17TH IEEE INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND APPLICATIONS (ICMLA), 2018, : 305 - 310
  • [34] Numerical Eligibility Criteria in Clinical Protocols: Annotation, Automatic Detection and Interpretation
    Claveau, Vincent
    Silva Oliveira, Lucas Emanuel
    Bouzille, Guillaume
    Cuggia, Marc
    Cabral Moro, Claudia Maria
    Grabar, Natalia
    ARTIFICIAL INTELLIGENCE IN MEDICINE, AIME 2017, 2017, 10259 : 203 - 208
  • [35] Eligibility criteria for phase I clinical trials: tight vs loose?
    Laeeq Malik
    David Lu
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 999 - 1002
  • [36] Leveraging Real-World Data for the Selection of Relevant Eligibility Criteria for the Implementation of Electronic Recruitment Support in Clinical Trials
    Melzer, Georg
    Maiwald, Tim
    Prokosch, Hans-Ulrich
    Ganslandt, Thomas
    APPLIED CLINICAL INFORMATICS, 2021, 12 (01): : 17 - 26
  • [37] Unnecessary exclusion: Eligibility criteria in gynecologic oncology interventional clinical trials impair access to trials
    Holtzman, Sharonne
    Letchinger, Riva
    Liu, Daniel
    Singh, Sunidhi
    Zamarin, Dmitriy
    Zakashansky, Konstantin
    Blank, Stephanie
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S449 - S449
  • [38] Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions
    Rahman, Nam Atiqur
    Ison, Gwynn
    Beaver, Julia A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 419 - 421
  • [39] Risk analysis of the differences in eligibility criteria between monarchE and POTENT clinical trials
    Yu, Muhan
    Takada, Mamoru
    Yamada, Hideyuki
    Fujimoto, Hiroshi
    Sakakibara, Junta
    Yamamoto, Hiroto
    Nagashima, Takeshi
    Otsuka, Masayuki
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials
    Denicoff, Andrea M.
    Ivy, S. Percy
    Tamashiro, Tami T.
    Zhao, Jinxiu
    Worthington, Katherine H.
    Mooney, Margaret M.
    Little, Richard F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (11): : 1437 - 1440